

West Virginia Pharmacy Services



Drug Utilization Review

2nd Quarter 2024

Prepared by : **gainwell**



WVDRGS044

DUR Quarterly Overall Summary Report

Report Period from 04/01/2024 thru 06/30/2024

Categories	2nd Qtr 2024	2nd Qtr 2023	% Change
Total Paid Amount	\$238,450,866.59	\$262,854,215.75	-9.28
Eligible Members	470,122	609,064	-22.81
Utilizing Eligibles	237,347	289,284	-17.95
Total # Prescriptions	1,991,244	2,349,433	-15.25
Cost per Utilizing Member	\$1,004.65	\$908.64	10.57
Average # Prescriptions per Utilizer	8	8	0.00
Average Cost per Prescription	\$119.75	\$111.88	7.03
# Generic Prescriptions	1,727,335	2,011,257	-14.12
% Generic Prescriptions	86	85	1.18
Total Cost - Generics	\$36,293,883.38	\$40,372,168.52	-10.10
Average Generic Prescription Cost	\$21.01	\$20.07	4.67
Average Days Supply - Generics	32	31	3.23
# Brand Prescriptions	263,909	338,176	-21.96
% Brand Prescriptions	13.00	14.00	-7.14
Total Cost - Brand	\$202,156,983.21	\$222,482,047.23	-9.14
Average Brand Prescription Cost	\$766.01	\$657.89	16.43
Average Days Supply - Brand	25	25	0.00
Rebates Collected	\$159,105,774.56	\$176,928,767.22	-10.07

Drug Utilization Review Board Meeting

08/05/2024

Disclaimer: This report is for trending purposes only and is not intended to match other financial reports



WVDRGS050

Top 25 Therapeutic Classes By Prescription Count

Report Period from 04/01/2024 thru 06/30/2024


Reporting Months (2nd Quarter) 04/01/2024 - 06/30/2024

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONVULSANTS	H4B	97,443	4.80	\$4,258,496.05
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	93,480	4.60	\$20,671,952.26
3	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	79,453	3.90	\$919,410.46
4	ANTIHISTAMINES - 2ND GENERATION	Z2Q	68,296	3.40	\$885,886.66
5	PROTON-PUMP INHIBITORS	D4J	66,153	3.30	\$1,052,164.39
6	ANTHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB (STATINS)	M4D	54,501	2.70	\$654,892.29
7	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	S2B	52,836	2.60	\$721,619.54
8	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	49,894	2.50	\$2,227,004.03
9	VITAMIN D PREPARATIONS	C6D	49,144	2.40	\$477,614.17
10	PENICILLIN ANTIBIOTICS	W1A	44,165	2.20	\$603,401.91
11	BETA-ADRENERGIC BLOCKING AGENTS	J7C	40,378	2.00	\$617,208.77
12	ANTIHISTAMINES - 1ST GENERATION	Z2P	38,783	1.90	\$509,457.49
13	ANTI-PSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONIST	H7T	37,484	1.90	\$5,475,438.63
14	GLUCOCORTICOIDS	P5A	36,674	1.80	\$996,517.97
15	SKELETAL MUSCLE RELAXANTS	H6H	32,738	1.60	\$398,201.59
16	ANTI-HYPERTENSIVES, ACE INHIBITORS	A4D	30,404	1.50	\$349,041.69
17	ANTIEMETIC/ANTI-VERTIGO AGENTS	H6J	29,813	1.50	\$439,554.67
18	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	29,317	1.50	\$457,176.94
19	THYROID HORMONES	P3A	28,073	1.40	\$525,970.90
20	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	27,687	1.40	\$731,560.38
21	LEUKOTRIENE RECEPTOR ANTAGONISTS	Z4B	27,664	1.40	\$348,725.06
22	ANTI-ANXIETY DRUGS	H2F	26,770	1.30	\$346,086.33
23	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	H7E	25,863	1.30	\$298,080.74
24	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	25,139	1.20	\$2,249,788.76
25	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	24,838	1.20	\$3,130,689.04
Totals:			1,116,990	55.30	\$49,345,940.72

WV POS Quarterly Drug Class Review Top 12 by Rx Count

Reporting Period From: 04/01/2024 - 06/30/2024

Reporting Months (2nd Quarter): 04/01/2024 - 06/30/2024



Amount Paid	
ANTICONSULSANTS	\$4,258,496.05
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	\$20,671,952.26
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$919,410.46
ANTIHISTAMINES - 2ND GENERATION	\$885,886.66
PROTON-PUMP INHIBITORS	\$1,052,164.39
ANTIHYPERTENSIVE-HMGCOA REDUCTASE INHIB(STATINS)	\$654,892.29
NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	\$721,619.54
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	\$2,227,004.03
VITAMIN D PREPARATIONS	\$477,614.17
PENICILLIN ANTIBIOTICS	\$603,401.91
BETA-ADRENERGIC BLOCKING AGENTS	\$617,208.77
ANTIHISTAMINES - 1ST GENERATION	\$509,457.49



WVDRGS029

Top 25 Therapeutic Classes by Amount Paid

Report Period from 04/01/2024 thru 06/30/2024


Reporting Months (2nd Quarter): 4/1/2024-06/30/2024

Rank	Therapeutic Class	Therapeutic Class Codes	Amount Paid	% of Total Amount Paid	Prescription Count
1	ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR AGONIST)	C4I	\$20,762,597.74	8.70	23,555
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	\$20,671,952.26	8.60	93,480
3	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$18,633,062.76	7.80	2,194
4	ANTIHYPERGLYCEMIC-SODIUM/GLUCOCOTRANSPORTER(SGLT2) INHIBITORS	C4D	\$8,970,506.13	3.70	11,037
5	CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	B0F	\$7,122,388.71	3.00	289
6	ANTI-NEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$6,664,626.82	2.80	462
7	INSULINS	C4G	\$5,537,822.06	2.30	22,100
8	ANTI-PSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONISTS	H7T	\$5,475,438.63	2.30	37,484
9	DIRECT FACTOR XA INHIBITORS	M9V	\$5,198,241.39	2.20	7,393
10	HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMBINATIONS	W0E	\$4,821,491.97	2.00	380
11	ANTI-PSEUDOMONAS AGENTS, SYSTEMIC	L1A	\$4,550,091.13	1.90	501
12	ARV-NUCLEOSIDE, NUCLEOTIDE RTI, INTEGRASE INHIBITORS	W5X	\$4,522,478.64	1.90	1,197
13	BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	B63	\$4,490,713.92	1.90	19,423
14	ANTICONVULSANTS	H4B	\$4,258,496.05	1.80	97,443
15	HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	W0B	\$3,519,489.08	1.50	502
16	HUMAN INTERLEUKIN 12/23 (IL-12/13) INHIBITORS, MAB	Z2U	\$3,432,725.33	1.40	131
17	INTERLEUKIN-4(IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	V4D	\$3,311,719.82	1.40	870
18	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	H2V	\$3,130,689.04	1.30	24,838
19	DIABETIC SUPPLIES	Y9A	\$3,081,352.16	1.30	8,239
20	HEMOPHILIA TREATMENT AGENTS, NON-FACTOR REPLACEMENT	M0P	\$2,872,960.06	1.20	79
21	ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	B61	\$2,775,813.63	1.20	5,126
22	ANTI-PSYCHOTIC-ATYPICAL, D3/D2 PARTIAL AG-5HT MIXED	H8W	\$2,672,864.55	1.10	2,031
23	ANTI-PSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$2,478,697.23	1.00	13,882
24	ANTIHYPERGLYCEMIC, DPP-4 INHIBITORS	C4J	\$2,474,727.99	1.00	3,414
25	ANTI-MIGRAINE PREPARATIONS	H3F	\$2,284,267.68	1.00	11,326
Totals:			\$153,715,214.78	64.30	387,376

Top 12 Therapeutic Classes by Amount Paid

Reporting Months 2nd Quarter: 4/1/2024-06/30/2024

Reporting Months (2nd Quarter): 4/1/2024-06/30/2024



Prescriptions

ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR AGONIST)	23,555
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	93,480
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	2,194
ANTIHYPERGLYCEMIC-SODIUM/GLUCOCOTRANSPORT2(SGLT2) INH	11,037
CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	289
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	462
INSULINS	22,100
ANTIPSYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGONIST	37,484
DIRECT FACTOR XA INHIBITORS	7,393
HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMB	380
ANTIPSORIATIC AGENTS,SYSTEMIC	501
ARV-NUCLEOSIDE,NUCLEOTIDE RTI,INTEGRASE INHIBITORS	1,197


Pharmacy Generic Utilization Summary by Amount Paid

Reporting Month 2nd Quarter: 4/1/2024-06/30/2024

Reporting Months (2nd Quarter): 4/1/2024-06/30/2024

Generic Utilization Summary

by Amount Paid



■	BNG	\$162,662,041	68.1 %
■	BWG	\$39,681,254	16.6 %
■	GEN	\$36,605,561	15.3 %
	Total	\$238,948,856	100.0 %

BNG = Brand With no Generic Available


BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy Generic Utilization Summary By Number Of Prescriptions

Report Period from 04/01/2024 thru 06/30/2024

Reporting Months (2nd Quarter): 4/1/2024-06/30/2024




BNG = Brand With no Generic Available

BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy DUR Savings - QUARTERLY
Report Period from 04/01/2024 thru 06/30/2024

Reporting Months (2nd Quarter) : 4/1/2024 - 6/30/2024



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$1,107,679.12	2.00
ER	Early Refill	\$29,574,569.89	61.00
HD	High Dose	\$1,074,461.80	2.00
ID	Ingredient Duplication	\$1,762,416.30	4.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$303,463.98	1.00
TD	Therapeutic Duplication	\$14,860,600.32	31.00
Totals:		\$48,683,191.42	100.00